Genmab's Rina-S improves progression-free survival in Phase 3 ovarian cancer trial

Bitget2026/10/23 15:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab's investigational Rina-S significantly improved progression-free survival and overall survival versus chemotherapy in the Phase 3 RAINFOL-02 trial for platinum-resistant ovarian cancer.
Rina-S reduced the risk of disease progression or death by 71%; the risk of death fell 57% in the intent-to-treat population.
The intent-to-treat population included 584 patients, regardless of folate receptor alpha expression or prior mirvetuximab treatment.
The safety profile remained consistent with previous findings, with no new safety signals or unexpected concerns.
Based on the results, Genmab plans to discuss potential next steps with regulatory authorities worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023662606) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab's Rina-S improves progression-free survival in Phase 3 ovarian cancer trial

You may also like

Crypto prices